Chugai Pharmaceutical Co., Ltd. (CHGCF)

Market Cap	67.96B
Revenue (ttm)	7.97B
Net Income (ttm)	2.70B
Shares Out	n/a
EPS (ttm)	1.64
PE Ratio	n/a
Forward PE	n/a
Dividend	0.26 (0.57%)
Ex-Dividend Date	Jun 27, 2024

Volume	3,732
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	29.04 - 50.31
Beta	0.53
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu,...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,604
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCF

Financial Performance

In 2023, Chugai Pharmaceutical's revenue was 1.11 trillion, a decrease of -11.79% compared to the previous year's 1.26 trillion. Earnings were 325.47 billion, a decrease of -13.08%.

Financial numbers in JPY